Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Target:
CLDN18.2
ELISA plates were pre-coated with 0.5 µg/per well purified human CLDN18.2-EGFP-VLP. Serial diluted Anti-CLDN18.2 monoclonal antibody (orb1173630) solutions were added, washed, and incubated with secondary antibody before ELISA reading. From above data, the EC50 for anti- CLDN18.2 monoclonal antibody binding with CLDN18.2-EGFP-VLP is 877.5 ng/ml.
FACS analysis of CLDN18.2 VLP A. Negative Control 1: Expi293 cells were stained with Fluorescent Human CLDN18.2 Full Length Protein-VLP (EGFP). B. Negative Control 2: Anti-GPRC5D-CAR-Expi293 cells (an irrelevant CAR) were stained with Fluorescent Human CLDN18.2 Full Length Protein-VLP (EGFP). C. Positive Control: Anti-CLDN18.2-CAR-Expi293 cells were stained with biotin labeled Protein L, followed by streptavidin-APC antibody. D. Anti-CLDN18.2-CAR-Expi293 cells were stained with Fluorescent Human CLDN18.2 Full Length Protein-VLP (EGFP).
* VAT and and shipping costs not included. Errors and price changes excepted
